Teneligliptin Hydrobromide Hydrate
[CAS# 1572583-29-9]

Identification

• Classification: Pharmaceutical intermediate >> API intermediate
• Name: Teneligliptin Hydrobromide Hydrate
• Synonyms: [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone;hydrate pentahydrobromide
• Molecular Formula: C₄₄H₆₇Br₅N₁₂O₃S₂
• Molecular Weight: 1275.73
• CAS Registry Number: 1572583-29-9
• SMILES: CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5.CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5.O.Br.Br.Br.Br.Br

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H315-H319-H335
• Safety Statements: P261-P264-P264+P265-P270-P271-P280-P301+P317-P302+P352-P304+P340-P305+P351+P338-P319-P321-P330-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Discovery and Applications

Teneligliptin Hydrobromide Hydrate is a medication primarily used in the treatment of type 2 diabetes. It is a DPP-4 (dipeptidyl peptidase-4) inhibitor, which works by blocking the action of the DPP-4 enzyme. This enzyme normally breaks down incretin hormones, which are involved in regulating blood sugar levels. By inhibiting DPP-4, Teneligliptin increases the levels of these hormones, leading to improved insulin secretion and a reduction in blood glucose levels.

Teneligliptin Hydrobromide Hydrate was developed by the pharmaceutical company Takeda and is marketed in several countries for the management of type 2 diabetes. It is typically used when diet and exercise alone do not adequately control blood sugar levels. The drug is often prescribed in combination with other antihyperglycemic agents such as metformin or sulfonylureas.

The compound is well-established in clinical practice, and numerous studies have confirmed its effectiveness and safety profile. Research has demonstrated that Teneligliptin is effective at lowering HbA1c levels (a key indicator of long-term blood sugar control), and it has been shown to have a relatively low risk of causing hypoglycemia compared to some other diabetic medications. It is typically well-tolerated, with the most common side effects being gastrointestinal in nature.

Teneligliptin’s pharmacokinetic properties have been thoroughly evaluated. After oral administration, the drug is absorbed into the bloodstream and reaches peak plasma concentrations within a few hours. It undergoes minimal metabolism, primarily by the liver, and is excreted largely unchanged in the urine.

As a DPP-4 inhibitor, Teneligliptin Hydrobromide Hydrate has been studied alongside other drugs in this class, such as sitagliptin and vildagliptin, and has been found to be comparably effective in managing blood glucose levels. It is typically prescribed for patients who require additional glycemic control after other first-line therapies, such as metformin, have proven insufficient.

Overall, Teneligliptin Hydrobromide Hydrate has a proven clinical track record as an effective treatment for type 2 diabetes and continues to be a useful therapeutic option for patients worldwide.

References

none